ArticleThe oncologist2025

First-line atezolizumab/bevacizumab or durvalumab/tremelimumab in advanced hepatocellular carcinoma: a real world, multicenter retrospective study.

Ioannis Kournoutas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.